Clinical Trial Update: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

View source ↗

Summary

Clinical trial update notes dyspnea and cardiotoxicity in multiple myeloma patients treated with carfilzomib, with the study subsequently terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Kyprolis (carfilzomib)

Snippet

Sponsor: University of Chicago | Conditions: Multiple Myeloma, Shortness of Breath | Status: TERMINATED